Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) have both developed effective treatments for a rare nerve disorder known as familial amyloid polyneuropathy (FAP). Which drug is better? Dueling clinical trial presentations made Thursday at a research meeting in Paris gave investors a unique opportunity to compare.

The winner: Alnylam.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.